Lyra Therapeutics Inc [NASDAQ: LYRA] closed the trading session at $20.25.
The stocks have a year to date performance of 96.22 percent and weekly performance of 341.18 percent. The stock has been moved at 104.24 percent over the last six months. The stock has performed 263.23 percent around the most recent 30 days and changed 108.33 percent over the most recent 3-months.
If compared to the average trading volume of 69.15K shares, LYRA reached to a volume of 26679559 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Lyra Therapeutics Inc [LYRA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LYRA shares is $65.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LYRA stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Lyra Therapeutics Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on May 07, 2024. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $12 to $2. The new note on the price target was released on May 07, 2024, representing the official price target for Lyra Therapeutics Inc stock.
The Average True Range (ATR) for Lyra Therapeutics Inc is set at 3.11, with the Price to Sales ratio for LYRA stock in the period of the last 12 months amounting to 22.54. The Price to Book ratio for the last quarter was 6.89, with the Price to Cash per share for the same quarter was set at 23.96.
LYRA stock trade performance evaluation
Lyra Therapeutics Inc [LYRA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 341.18. With this latest performance, LYRA shares gained by 263.23% in over the last four-week period, additionally plugging by 104.24% over the last 6 months – not to mention a rise of 22.36% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LYRA stock in for the last two-week period is set at 90.94, with the RSI for the last a single of trading hit 94.76, and the three-weeks RSI is set at 86.60 for Lyra Therapeutics Inc [LYRA]. The present Moving Average for the last 50 days of trading for this stock 5.73, while it was recorded at 7.79 for the last single week of trading, and 9.88 for the last 200 days.
Lyra Therapeutics Inc [LYRA]: An insightful look at the core fundamentals
Lyra Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.96 and a Current Ratio set at 2.96.
Earnings per share (EPS) analysis for Lyra Therapeutics Inc [LYRA] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LYRA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lyra Therapeutics Inc go to 21.95%.
Lyra Therapeutics Inc [LYRA]: Institutional Ownership
The top three institutional holders of LYRA stocks are: PERCEPTIVE ADVISORS LLC with ownership of 12.76 million shares, which is approximately 19.4892%. CITADEL ADVISORS LLC, holding 4.77 million shares of the stock with an approximate value of $$1.32 million in LYRA stocks shares; and CITADEL ADVISORS LLC, currently with $$0.78 million in LYRA stock with ownership which is approximately 4.3232%.
